US FDA approves first nasal spray for allergic reactions (updated)

ARS Pharmaceuticals

09/08/2024 16:35

(Adds details in paragraphs 2 and 3, shares in paragraph 4)
       Aug 9 (Reuters) - The U.S. Food and Drug Administration
said on Friday it had approved ARS Pharmaceuticals'  SPRY.O 
nasal spray as the first needle-free emergency treatment for
potentially fatal allergic reactions.
    The spray, which will be sold under the brand name neffy,
was approved for use in adult and pediatric patients who weigh
at least 30 kilograms.
        Neffy is seen as an alternative to EpiPen and other
autoinjectors like Kaleo's Auvi-Q that are filled with
epinephrine, a life-saving drug used by people at risk of
anaphylaxis and other allergic reactions.
  
        Shares of ARS Pharmaceuticals rose about 3% after the
FDA's decision.
  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh
Kuber and Devika Syamnath)
 ((Sriparna.Roy@thomsonreuters.com;))